Fund Holdings — CAXTON CORP

Total Portfolio Value
$16.64M
Total Bought
$444.9K
Total Sold
$7.90M
Net Transaction
-$7.45M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q3 2024
▲▼
Q4 2024
▲▼
Change
▲▼
Q3 2024
▲▼
Q4 2024
▲▼
Weight (%)
▲▼
Change
▲▼
SPDR GOLD TR(GLD)01,169+1,16902831.70%+283
REZOLUTE INC(RZLT)1,318,9671,318,96706,3976,46338.85%+66
CARDIFF ONCOLOGY INC(CRDF)013,287+13,2870580.35%+58
INHIBIKASE THERAPEUTICS INC(IKT)016,393+16,3930530.32%+53
GLYCOMIMETICS INC0203,578+203,5780510.31%+51
MIND MEDICINE MINDMED INC34,07334,07301942371.43%+43
SPDR S&P 500 ETF TR(SPY)2,8672,823-441,6451,6549.94%+10
ADICET BIO INC17,48817,488025170.10%-8
BERKSHIRE HATHAWAY INC DEL1,1511,133-185305143.09%-16
CONTEXT THERAPEUTICS INC(CNTX)18,40318,403036190.12%-17
COMPASS THERAPEUTICS INC(CMPX)43,46543,465080630.38%-17
KYVERNA THERAPEUTICS INC(KYTX)22,98122,9810112860.52%-26
LEXEO THERAPEUTICS INC(LXEO)17,85117,85101611170.71%-44
BICARA THERAPEUTICS INC10,94110,94102791911.15%-88
ABIVAX SA(ABVX)11,3650-11,3651310—-131
XERIS BIOPHARMA HOLDINGS INC5,113,3482,015,157-3,098,19114,5736,83141.06%-7,742
Page 1 of 1
CAXTON CORP — 13F Holdings — Q4 2024 | TickerTrail